Side Event at EHA2024 Congress

Name: Tackling the implementation gap to improve early diagnosis and treatment for haematology patients

Location: Side Event at EHA2024 Congress venue – IFEMA MADRID RECINTO FERIAL (Fairgrounds), Madrid, Spain – ROOM N113

Date: Friday, June 14th, 2024

Time: 14.00 – 17.00 CEST

You can find the agenda here.

You can register for the event here.

The drivers of personalised medicine in haematology are clear: for patients (and physicians) – more options, durable clinical benefit, reduced exposure to non-effective drugs and potential to leverage current scientific and technological advances; for the Pharmaceutical industry – the potential to tackle core challenges in discovering and developing better and more efficacious medicines, to reduce rates of attrition in drug development and to reduce development costs; for healthcare systems and payers – improved efficiency through the provision of effective care and avoiding ineffective treatments.

Haematology has been at the vanguard, the improvements gained in patient survival notable. However, this poses significant challenges for healthcare systems and regulatory approval. Further substantial evolution of policy and processes, particularly regulatory requirements for approval for new therapeutics are required.

Different processes and metrics are required; new ways of working (together), and the need to ensure that the current misalignment does not hamper progress for the advancement towards better future healthcare provision. Ultimately, the patient benefits, but the system needs to be sustainable and deliverable. We consider this emerging landscape in the context of the development of novel therapeutics, and the challenges and adjustments required to permit (therapeutic/drug) development, and ultimately implementation in the clinic.

The focus of this expert panel is to address these challenges starting at the beginning: fundamentally, new science requires a strong preclinical platform of evidence to support clinical testing of a potential new therapeutic; clinical trial designs are needed that suit a more segmented patient population which in turn, demands new and robust methods for patient identification and selectio. Establishing the clinical evidence required to support development and (marketing) approval of a new therapeutic needs careful consideration, more extensive and mature collaboration between and amongst different sectors, and supported by new thinking in regulatory processes; and finally, an ability to implement and pay for the new therapy in routine clinical care requires an up-to-date understanding and new models of delivery. The bars for efficacy (clinical benefit) and finance suitability (cost-effective development, delivery, reimbursement) in developing and gaining market approval for a new precision medicine therapy become increasing high – and equally so, the challenges faced in the development process, operational delivery and clinical implementation. The potential benefits of precision medicine and the direction and barriers for development for new therapies are apparent, and we are beginning to realize the challenges faced. But, is precision medicine truly deliverable and what is required to get us there?

You can register for the event here.

You can find the agenda here.

If you like it, share it